A B S T R A C T Corticosteroids cauise an enhanced return of granulopoiesis as meastured by in vitro growth of grantulocytic progenitor cells (CFU-C) in mice treated with cyclophosphamide. After methylprednisolone and cyclophosphamide, a greater than threefold increase in marrow CFU-C was measured on day 4 compared to mice given cyclophosphamide alone (29,700+200 vs. 8,400+700/humerus). The accelerated return of marrow CFU-C was observed with cyclophosphamide in doses of 200 and 450 mg/kg and methylprednisolone, 2-20 mg/kg, with no significant differences using >5 mg/kg, and was detected when dexamethasone was used in place of methylprednisolone. This effect was accompanied by similarly enhanced splenic granulopoiesis as measured by CFU-C concentration. Levels of colony stimulating activity did not diffe-r in mice given methylprednisolone and cyclophosphamide or cyclophosphamide alone. Corticosteroids appear to enhance the return of CFU-C by altering the proliferative state of granulocytic progenitor cells. CFU-C survival to in vitro 3HTdR suicide increased from 72±4% on day 1 after cyclophosphamide to 90±+-6% in animals given both cyclophosphamide and methylprednisolone. Increased survival after 3HTdR suicide was also observed when methylprednisolone alone was given. After treatment with cyclophosphamide and methylprednisolone, blood neutrophils increased more rapidly and improved survival to infection with Candida albicans was observed. These studies demonstrate that corticosteroids have a beneficial effect on marrow regeneration after myelotoxic chemotherapy with cyclophosphamide and suggest that they act by altering cell cycle characteristics of granulocyte progenitor cells.
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INTRODUCTION
Marrow toxicity represents a major limitation to treatment of malignant disorders. Major efforts continue to be directed toward development of agents capable of improved destruction of malignant cells; however, studies designed to modify toxicity to normal marrow progenitor cells have been limited (1) (2) (3) (4) .
The technique of in vitro growth of colonies of granulocytes and mononuclear cells in semisolid media has been used to characterize the compartment of cells presumed to be committed stem cells (CFU-C)' in the marrow and blood (5, 6) . Recent reports have indicated increased granulopoietic recovery with this technique in mice made neutropenic by cytotoxic drugs when given androgenic steroids (7) . Adrenal cortical steroids are frequently used in combination with myelotoxic chemotherapy for treatment of malignancy. However, their effect on granulocyte kinetics, beyond causing release of cells from the marrow (8) and impaired migration of cells to exudates (9) , has not been investigated in regenerating marrow. The effect of corticosteroids on granulopoietic recovery in mice after myelotoxic treatment with cyclophosphamide forms the basis of this report.
METHODS
(C57B, female and DBA male) F1 female mice bred in our laboratory from stock purchased from The Jackson Laboratory, Bar Harbor, Me., were used in all experiments. Animals were between 9 and 15 wk of age.
Cyclophosphamide (Mead Johnson Laboratories, Evansville, Ind.), methylprednisolone (The Upjohn Comnpany, Kalamazoo, Mich.), and dexamethasone (Merck Sharp & Dohme, West Point, Pa.) were diluted in normal saline for injection. Control mice were saline injected. All drugs were given intraperitoneally in equivalent volumes. 1Abbreviations used in this paper: 3HTdR, tritiated thymidine; CFU-C, in vitro colony-forming cells; CSA, colony stimulating activity.
Quantitative marrow counts were made from cell suspensions obtained by gently flushing the isolated mouse humerus with tissue culture medium, CMRL 1066, as described previously (10) . Peripheral blood was obtained by orbital sinus puncture. Cell concentrations were measured with an electronic particle counter (Coulter Counter, Model B, Coulter Electronics Inc., Hialeah, Fla.) and from 200 cell differential counts of Wright's stained blood smears and 500 cell differential counts of cytocentrifuged marrow specimens. Spleen cell suspensions were obtained by gently flushing whole mouse spleens with culture media.
The concentrations of CFU-C from mouse marrow and spleen were determined by measuring colony formation in the soft gel system as described by Pluznik and Sachs (11) and by Bradley and Metcalf (12) . Methylcellulose (Dow Corning Corp., Midland, Mich.) was used in place of agar (13) . Cells were suspended in 1.8% methylcellulose containing culture medium CMRL 1066, 15% horse serum, and 10% L-cell conditioned medium. The combined mixture was then plated in triplicate in 1-ml volumes in culture dishes 35 x 10 mm, and incubated at 37°C in 7.5% CO2 for 7 days. Colonies containing more than 50 cells were counted with an inverted microscope.
Cell cycle characteristics of mouse CFU-C were measured by determining the degree to which colony forming capacity ofthe cultured cells was lost after tritiated thymidine (3HTdR) suicide as described by Iscove et al. (14) . phosphamide alone, 200 mg/kg, marrow CFU-C content was decreased by day 1 to 400±70/humerus. Thereafter CFU-C content increased to normal levels of 8,400+ 700 on day 4, reached peak values on day 5 (51,000+7,500), and then declined. In animals given methylprednisolone, 5 mg/kg, 3 h before cyclophosphamide, a decrease to 1,900± 100 CFU-C occuirred on day 1. However, by day 4 marrow CFU-C content increased to a level more than threefold greater than in mice given cyclophosphamide alone (29,700±200/humerus vs. 8, 400) . Peak values also occurred on day 5 (54,400 +2,500) followed by a decline. A similar effect on recovery of marrow CFU-C was observed in mice given methylprednisolone when maximally tolerated doses of cyclophosphamide, 450 mg/kg, were used compared with mice given this dose of cyclophosphamide alone. On day 1, CFU-C decreased to 20+4/humerus after cyclophosphamide, 450 mg/kg, and to 35±3 in mice given cyclophosphamide and methylprednisolone. Marrow CFU-C then increased in both groups. On day 4, mice treated with methylprednisolone and cyclophosphamide had more than twice the number of CFU-C per humeruLs (16,200+500) than mice given cyclophosphamide alone (6,800±500). Again there was no difference in maximum CFU-C concentration reached on day 5 (21,300+2,600 and 26,000+3,900, respectively).
The effect of methylprednisolone alone on marrow CFU-C is shown in Table I . On day 1 after treatment, the number of marrow CFU-C was significantly de- Table II . In a concentration of 0.1 ,ug or less, no effect on CFU-C was observed. However, the addition of methylprednisolone in concentrations of 1, 5, or 10 ,tg resulted in inhibition of CFU-C by 11, 17, and 24%, respectively. The accelerated return of marrow CFU-C in cyclophosphamide-treated mice receiving methylprednisolone was observed with methylprednisolone given in doses of [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] mg/kg 3 h before cyclophosphamide. Marrow CFU-C content was twofold greater on day 4 after methylprednisolone, 2 mg/kg, and cyclophosphamide than after cyclophosphamide alone (16,400+1,100 vs. 8,300±700/humerus). A maximum increase of threeto fourfold was observed in mice given methylprednisolone, 5 mg/kg (29,000 vs. 8,300), with no further increase in marrow CFU-C content observed when methylprednisolone in doses >5 mg/kg were used. When dexamethasone, 1 mg/kg, was used in place of methylprednisolone, a similar pattern of earlier recovery of marrow CFU-C was observed. Marrow CFU-C decreased to 1,500±+100/humerus on day 1 after cyclophosphamide, 200 mg/kg, and dexamethasone and increased to 31,500+5,300 by day 4 with maximum CFU-C concentration reached on day 5. To determine the optimal time for steroid administration to be effective, administration of methylprednisolone was varied relative to the time ofgiving cyclophosphamide. These results are seen in Table III. Marrow CFU-C were similarly reduced during the first three days after treatment with cyclophosphamide regardless of the time of administration of methylprednisolone. However, the administration of methylprednisolone at 12 or 24 h before cyclophosphamide resulted in a significant increase in CFU-C content to 17,400 and 18,400, respectively, on day 4 compared with controls not receiving methylprednisolone (8, 400) . However, the effect of methylprednisolone was most marked when given 3 h before cyclophosphamide at which time an increase to 29,700+200 was observed. Giving methylprednisolone simultaneously or 48 h before cyclophosphamide resulted in a slight but nonsignificant increase in CFU-C and no increase was observed when methylprednisolone was given 18 h after cyclophosphamide.
To determine the effect of methylprednisolone on splenic granulopoiesis in mice given cyclophosphamide, spleen cells obtained from mice after treatment with cyclophosphamide with and without methylprednisolone were assayed for CFU-C content (Table IV) . The pattern was similar to that observed in the marrow. There was no significant difference in CFU-C concentration in the spleen 1 day after treatment. However, by day 4 mice given methylprednisolone contained a nearly twofold greater concentration of To determine whether the accelerated return of CFU-C in cyclophosphamide-treated mice given methylprednisolone was the result of increased levels of colony stimulating activity (CSA), sera from mice given cyclophosphamide alone or cyclophosphamide with methylprednisolone were tested for CSA in cultures of normal mouse marrow cells (Table V) . Sera from mice given either cyclophosphamide or cyclophosphamide plus methylprednisolone contained increased levels of CSA by day 2 after treatment with little difference between the two groups. Thereafter levels remained elevated through day 5, returning to control values by day 7. The effect of corticosteroids on the cell cycle characteristics of CFU-C from mice given cyclophosphamide or cyclophosphamide and methylprednisolone was measured by determining the percent survival of CFU-C after in vitro exposure to 3HTdR (Table VI) . On day 1 in mice given cyclophosphamide and methylprednisolone, a significant increase in survival of CFU-C was observed after exposure to 3HTdR (90±6%) compared with either controls or to mice given cyclophosphamide alone (72±4%, P < 0.025). This difference was less on day 2, and by day 3 Table IV. group given only cyclophosphamide. Enhanced survival after 3HTdR suicide was also observed on days 1 and 2 in mice given methylprednisolone alone compared with untreated controls.
Although there was no difference in quantitative marrow counts between cyclophosphamide-or cyclophosphamide-and methylprednisolone-treated mice, a difference in blood neutrophil concentration was observed as shown in Fig. 2 . During the first 4 days after treatment, neutrophil concentrations decreased in both groups. Thereafter, blood neutrophil concentrations increased more rapidly in mice given methylprednisolone and cyclophosphamide, reaching levels of 9,600+600 and 11,700±1,900/,ul on days 7 and 8 compared with 6,800+700 and 9,000±700/,ul in mice given only cyclophosphamide (P < 0.05). Neutrophil counts then declined toward control values in both groups by days 10 and 12 after treatment. To determine if the enhanced recovery of granulopoiesis using methylprednisolone in combination with cyclophosphamide might have a beneficial effect in combating infection, the survival of mice infected with C. albicans was stuLdied. Groups of 50 mice were given 107 C. albicans intraperitoneally on the 2nd day and after administration of cyclophosphamide or cyclophosphamide and methylprednisolone at a time when blood neuitrophil concentrations were decreasing in both grouips. As shown in Fig. 3 , a significant improvement in survival was observed in mice given cyclophosphamide and methylprednisolone by day 4 of infection (62 vs. 36% survival). No additional deaths occturred after day 8 of infection. There were no deaths in uintreated mice given C. albicans or in mice treated with methylprednisolone alone 2 days before C. infection. No difference in survival was noted when Candida was given at earlier time intervals after druig treatment.
DISCUSSION
These studies demonstrate that corticosteroids enhance grantulopoietic recovery in mice treated with cyclophosphamide. The degree of enhanced recovery with methylprednisolone is dose dependent, present within a wide dose range of cyclophosphamide, and is dependent on the time of administration of corticosteroids relative to treatInent with cycloplhospha- treatment has been demonstrated in previous reports (17, 18) . Corticosteroids appear to enhance the return of CFU-C after cyclophosphamide treatment of mice by altering the proliferative state of granulocytic progenitor cells. Treatment with methylprednisolone alone resulted in increased CFU-C survival to 3HTdR suicide for 2 days after treatment. Similar changes in cell cycle were observed when methylprednisolone was given to cyclophosphamide-treated mice. The data suggest that a larger portion of precursor cells are removed from replicative cycle by corticosteroid treatment, allowing them to escape the cytotoxic effects of cyclophosphamide early after treatment. By day 4, survival of CFU-C after 3HTdR decreased in cyclophosphamide-and methylprednisolone-treated mice. This corresponded to the time of increased proliferation of CFU-C in those mice compared to mice given only cyclophosphamide.
The earlier return of CFU-C did not appear related to changes in serum CSA levels in cyclophosphamidetreated mice given methylprednisolone. In animals receiving cyclophosphamide alone or cyclophosphamide and methylprednisolone, serum CSA increased to similar levels by day 2 after treatment and corresponded to the onset of peripheral neutropenia. CSA levels remained elevated until day 7 when peripheral neutrophilia was observed. Craddock and co-workers (19) reported reduced colony formation in human subjects treated with high-dose methylprednisolone for renal allograph rejection and suggested that steroids cause a decrease in generation of CSA in vitro. Metcalf (20) has also suggested that colony number and size are influenced by changes in CSA release by the marrow cells in vitro. Although differences in colony number were observed in cyclophosphamide-treated mice when given methylprednisolone, no difference in estimated colony size were observed between the two groups. It is possible that the enhanced granulopoiesis observed in methylprednisolone-treated mice may have been the result of altered metabolism of cyclophosphamide to its myelotoxic derivatives. Tredger et al. (21) have recently reported that whereas dexamethasone increases microsomal content and associated drug metabolizing enzyme activities in rat liver, no increase was observed with prednisolone. In the present study, similarly enhanced marrow CFU-C content was detected in cyclophosphamide-treated mice given either dexamethasone or methylprednisolone. Furthermore, the similarity of reduction of both quantitative marrow counts and blood neutrophil concentrations during the 3 days after treatment with cyclophosphamide wi.th or without methylprednisolone, while not demonstrating similarity of drug metabolism, suggests that alteration of cyclophosphamide metabolism due to corticosteroids was probably not a major factor contributing to the earlier recovery of granulopoiesis. That methylprednisolone alone alters granulocyte progenitor cells is further supported by the changes in CFU-C cell cycle observed in mice given methylprednisolone without cyclophosphamide.
Previous studies have demonstrated that mortality after C. albicans infection in mice treated with cyclophosphamide is related to the severity and duration of leukopenia (22) . In the present study, survival was greater when C. albicans was given to mice treated with cyclophosphamide and methylprednisolone than in mice treated with cyclophosphamide alone. This suggests that the enhanced granulopoiesis observed when methylprednisolone is given with cyclophosphamide is probably responsible for the improved ability to resolve subsequent infection. Even though the duration of neutropenia in uninfected animals treated with cyclophosphamide with or without methylprednisolone was similar, additional factors such as differences in neutrophil migration to areas of infection and host immune responses may also contribute to survival.
These studies indicate that corticosteroids enhance the return of CFU-C in cyclophosphamide-treated animals and suggest that corticosteroids act by altering cell cycle characteristics. The earlier return of marrow CFU-C is accompanied by a similar increase in spleen CFU-C, by a more rapid increase in blood neutrophils and by an improved tolerance to infection. These studies suggest that treatment with corticosteroids has a beneficial effect on normal marrow regeneration after myelotoxic chemotherapy with cyclophosphamide.
